These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 18559968)

  • 1. Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium.
    Chang SM; Lamborn KR; Kuhn JG; Yung WK; Gilbert MR; Wen PY; Fine HA; Mehta MP; DeAngelis LM; Lieberman FS; Cloughesy TF; Robins HI; Abrey LE; Prados MD;
    Neuro Oncol; 2008 Aug; 10(4):631-42. PubMed ID: 18559968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel endpoints and design of early clinical trials.
    Parulekar WR; Eisenhauer EA
    Ann Oncol; 2002; 13 Suppl 4():139-43. PubMed ID: 12401680
    [No Abstract]   [Full Text] [Related]  

  • 3. Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents.
    Ratain MJ; Mick R; Schilsky RL; Siegler M
    J Natl Cancer Inst; 1993 Oct; 85(20):1637-43. PubMed ID: 8411243
    [No Abstract]   [Full Text] [Related]  

  • 4. New designs for phase II trials: application to a trial of targeted therapies vs. chemotherapy in patients age > 60 with AML/high-risk MDS.
    Estey EH
    Ann Hematol; 2004; 83 Suppl 1():S94-6. PubMed ID: 15124692
    [No Abstract]   [Full Text] [Related]  

  • 5. Toward better early-phase brain tumor clinical trials: a reappraisal of current methods and proposals for future strategies.
    Lang FF; Gilbert MR; Puduvalli VK; Weinberg J; Levin VA; Yung WK; Sawaya R; Fuller GN; Conrad CA
    Neuro Oncol; 2002 Oct; 4(4):268-77. PubMed ID: 12356357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Operational complexity versus design efficiency: challenges of implementing a phase IIa multiple parallel cohort targeted treatment platform trial in advanced breast cancer.
    Snowdon C; Kernaghan S; Moretti L; Turner NC; Ring A; Wilkinson K; Martin S; Foster S; Kilburn LS; Bliss JM
    Trials; 2022 May; 23(1):372. PubMed ID: 35526005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium.
    Bautista F; Moreno L; Marshall L; Pearson ADJ; Geoerger B; Paoletti X
    Eur J Cancer; 2017 Nov; 86():275-284. PubMed ID: 29055843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and Phase II Objective Response Rates are Correlated in Pediatric Cancer Trials: An Argument for Better Clinical Trial Efficiency.
    Yeh JC; Huang P; Cohen KJ
    J Pediatr Hematol Oncol; 2016 Jul; 38(5):360-6. PubMed ID: 27164535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Innovation in oncology clinical trial design.
    Verweij J; Hendriks HR; Zwierzina H;
    Cancer Treat Rev; 2019 Mar; 74():15-20. PubMed ID: 30665053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Challenges and concerns in early-phase clinical trials].
    Gordin A; Scheinin H
    Duodecim; 1992; 108(11):1026-36. PubMed ID: 1366021
    [No Abstract]   [Full Text] [Related]  

  • 12. Methodologic guidelines for the design of high-dose chemotherapy regimens.
    Margolin K; Synold T; Longmate J; Doroshow JH
    Biol Blood Marrow Transplant; 2001; 7(8):414-32. PubMed ID: 11569887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Study of Regulatory Challenges of Pediatric Oncology Phase I/II Trial Submissions and Guidance on Protocol Development.
    Beck L; Witt R; Nesper-Brock M; Milde T; Hettmer S; Frühwald MC; Rössig C; Fischer M; Reinhardt D; Taylor LA; Riedel C; Witt O; van Tilburg CM
    Clin Pharmacol Ther; 2021 Oct; 110(4):1025-1037. PubMed ID: 34050933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current Landscape of Late-Phase Clinical Trials for Alzheimer's Disease: Comparing Regional Variation Between Subjects in Japan and North America.
    Kikuchi M; Adachi N; Matsumaru N; Tsukamoto K
    Pharmaceut Med; 2019 Dec; 33(6):511-518. PubMed ID: 31933241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Phases 0, 1 and 2 oncology clinical trials: current questions].
    Penel N; Fournier C; Stéphanie C
    Bull Cancer; 2010 Jan; 97(1):55-63. PubMed ID: 20080458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent innovations in the USA National Cancer Institute-sponsored investigator initiated Phase I and II anticancer drug development.
    Bando H; Takebe N
    Jpn J Clin Oncol; 2015 Nov; 45(11):1001-6. PubMed ID: 26423340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee.
    Ivy SP; Siu LL; Garrett-Mayer E; Rubinstein L
    Clin Cancer Res; 2010 Mar; 16(6):1726-36. PubMed ID: 20215542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The strategy of combination phase I/II study].
    Murakami H; Ohe Y; Saijo N
    Gan To Kagaku Ryoho; 2000 Nov; 27(13):2151-4. PubMed ID: 11103251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of the Innovative Therapies for Children With Cancer Consortium Trial Portfolio for Drug Development for Children With Cancer.
    Bautista F; Verdú-Amorós J; Geoerger B; Rubio-San-Simón A; Paoletti X; Zwaan CM; Casanova M; Marshall LV; Carceller F; Doz F; Lecinse C; Vassal G; Pearson ADJ; Kearns P; Moreno L;
    J Clin Oncol; 2024 Jul; 42(21):2516-2526. PubMed ID: 38743911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation and recommendations on good clinical laboratory practice guidelines for phase I-III clinical trials.
    Sarzotti-Kelsoe M; Cox J; Cleland N; Denny T; Hural J; Needham L; Ozaki D; Rodriguez-Chavez IR; Stevens G; Stiles T; Tarragona-Fiol T; Simkins A
    PLoS Med; 2009 May; 6(5):e1000067. PubMed ID: 19536325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.